N/A N=21 Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
Inflammation · Atherosclerosis · Cardiovascular Disease
Primary: Inflammation Change: HDL Plasma — NA; NA AU
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=149 Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles
Cheek Wrinkles
Primary: Responder Rate Based on the Blinded Evaluator's Live Assessment of the Galderma Cheek Wrinkles Scale (GCWS) at Rest at Month 12 — 26.1; 71.6 percentage of participants…
N/A N=47 Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia
Vulvar Intraepithelial Neoplasia (VIN)
Primary: Number of Participants With Recurrence of Dysplasia — 5; 8 Participants
N/A N=20 Pilot Study Evaluating the Acceptability and Absorption of the Bioactive Compounds of a Russian Tarragon Nutrasorb Bar
Diabetes Prevention
Primary: Palatability of Bar — 77.4; 59.5; 27.8; 50.6 score on a scale
Phase 2 N=35 Single-agent Cobimetinib for Adults With Histiocytic Disorders
Histiocytic Disorders
Primary: Best Overall Response — 21; 5; 3; 6 Participants
Phase 3 N=1,251 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Metastatic Hormone-Sensitive Prostate Cancer
Primary: Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as…
Phase 2 N=119 COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
Multiple Myeloma · AL Amyloidosis · Chronic Lymphocytic Leukemia
Primary: Observed Response Rate of Anti-SARS-CoV2 Antibody Seroconversion. — 29; 28; 0 Participants
Phase 2 N=14 A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults
HIV Infections
Primary: Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase — 12258.5; 30833.0; 25466.0; 25689.5…
Phase 2 N=11 Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
HER2-positive Breast Cancer · Breast Adenocarcinoma · Stage II Breast Cancer AJCC v6 and v7
Primary: Percentage of Participants With Grade 3 or Greater Diarrhea — 29; 50 percentage of participants
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
N/A N=12 Acceptance and Commitment Therapy for Aging People Living With HIV in Chronic Pain
HIV/AIDS · Chronic Pain
Primary: Change in Chronic Pain Acceptance Questionnaire (CPAQ) Week 0 to Week 6 — 5; 13 score on a scale
N/A N=133 Exercise Intervention for LGBT Cancer Survivors
Neoplasms
Primary: Self-Reported Psychological Distress — 8.89; 6.96 score on a scale
Phase 1 N=44 Intestinal Permeability in Preterm Infants
Prematurity · Intestinal Permeability
Primary: Intestinal Permeability — 0.0731; 0.0720 ratio — p=0.932
Phase 3 N=167 An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
Acute Lymphoblastic Leukemia · Lymphoblastic Leukemia
Primary: Response Rate During the First Course of JZP-458 Administration — 18; 70; 44; 20 Participants
Phase 2 N=122 A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
Pulmonary TB
Primary: Stage 1: Change From Baseline in TB Bacterial Load in Sputum as a Measure of Early Bactericidal Activity (EBA) — -1.93; -2.12; -2.08; -1.69 sputum log10CFU/mL